Acetyl-L-carnitine in neuropathic pain: experimental data.
Acetyl-L-carnitine (ALC) has gained clinical interest for its analgesic effect in different forms of neuropathies associated with chronic pain, such as diabetic and HIV-related peripheral neuropathies. The antinociceptive effect of ALC has been confirmed in several experimental models of neuropathic pain, including streptozotocin- and chemotherapy-induced neuropathy, and the sciatic nerve chronic constriction injury model. In these models, prophylactic administration of ALC has proven to be effective in preventing the development of neuropathic pain. In addition, ALC is known to produce a strong antinociceptive effect when given after neuropathic pain has been established. ALC can also improve the function of peripheral nerves by increasing nerve conduction velocity, reducing sensory neuronal loss, and promoting nerve regeneration. Analgesia requires repeated administrations of ALC, suggesting that the drug regulates neuroplasticity across the pain neuraxis. Recent evidence indicates that ALC regulates processes that go beyond its classical role in energy metabolism. These processes involve the activation of muscarinic cholinergic receptors in the forebrain, and an increased expression of type-2 metabotropic glutamate (mGlu2) receptors in dorsal root ganglia neurons. Induction of mGlu2 receptors is mediated by acetylation mechanisms that involve transcription factors of the nuclear factor (NF)-kappaB family.
Chiechio
Santina
S
Department of Pharmaceutical Sciences, University of Catania, Catania, Italy.
Copani
Agata
A
Gereau
Robert W
RW
Nicoletti
Ferdinando
F
D000108:Acetylcarnitine / Q000627:therapeutic use*; D000698:Analgesia; D000818:Animals; D006801:Humans; D018697:Nootropic Agents / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D018094:Receptors, Metabotropic Glutamate / Q000235:genetics / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000187:drug effects; D010738:Type C Phospholipases / Q000378:metabolism
D018697:Nootropic Agents; D018094:Receptors, Metabotropic Glutamate; D011976:Receptors, Muscarinic; C108822:metabotropic glutamate receptor 2; D000108:Acetylcarnitine; D010738:Type C Phospholipases
Farmaco. 2001 May-Jul;56(5-7):383-5
11482763
Brain Res Dev Brain Res. 1999 Jan 11;112(1):39-53
9974158
J Neurophysiol. 2006 Oct;96(4):1803-15
16760343
Neurosci Lett. 2000 Jun 30;287(3):236-8
10863038
Science. 2000 Jun 9;288(5472):1765-9
10846153
Life Sci. 1996;58(12):991-1000
8786711
J Neurosci Res. 1988 Aug;20(4):491-6
2846861
Diabetologia. 1995 Jan;38(1):123
7744218
Mol Pain. 2006 Jun 09;2:20
16764720
Drug Saf. 1998 Dec;19(6):481-94
9880091
Tumori. 2005 Mar-Apr;91(2):135-8
15948540
J Biol Chem. 2002 Feb 15;277(7):4973-80
11739381
Neuropsychopharmacology. 2003 May;28(5):888-97
12736633
Br J Pharmacol. 2002 Mar;135(5):1255-62
11877334
Metabolism. 1995 May;44(5):677-80
7752919
Mol Pharmacol. 2002 May;61(5):989-96
11961116
Neuropharmacology. 2002 Dec;43(7):1180-7
12504925
AIDS. 2004 Jul 23;18(11):1549-60
15238773
Cell. 2003 Jan 10;112(1):113-22
12526798
Biochim Biophys Acta. 1986 Mar 21;876(1):175-7
3081044
J Physiol. 2002 Sep 15;543(Pt 3):807-18
12231640
Diabetes Care. 2005 Jan;28(1):89-94
15616239
Neuroscience. 2000;100(2):393-406
11008177
Drugs R D. 2002;3(4):223-31
12455197
J Pharmacol Exp Ther. 1998 Dec;287(3):897-902
9864270
Br J Pharmacol. 2000 Apr;129(8):1633-40
10780968
Pain. 2004 Jan;107(1-2):22-32
14715385
J Neurochem. 2001 Dec;79(5):959-69
11739607
In Vivo. 2005 May-Jun;19(3):631-7
15875786
J Neurosci. 2002 Aug 1;22(15):6388-93
12151517
Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):283-96
12769620
Br J Pharmacol. 1992 Jan;105(1):77-82
1375858
Physiol Rev. 1983 Oct;63(4):1420-80
6361812
Clin Ther. 2000 Aug;22(8):911-36; discussion 898
10972629
J Comp Neurol. 1999 Aug 9;410(4):627-42
10398053
Pharmacol Biochem Behav. 2002 Sep;73(2):419-27
12117597
Clin Cancer Res. 2003 Nov 15;9(15):5756-67
14654561
J Clin Invest. 1996 Apr 15;97(8):1900-7
8621774
Support Care Cancer. 2004 Sep;12(9):619-25
15258838
Pain. 2003 Dec;106(3):411-7
14659524
Neuroreport. 1997 Aug 18;8(12):2695-9
9295103
Biopharm Drug Dispos. 2003 Nov;24(8):357-65
14595704
EMBO Rep. 2003 Oct;4(10):944-7
14528264
Neurosci Lett. 2002 Dec 16;334(3):181-5
12453625
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jun 1;9(2):153-61
7749792
Anesth Analg. 1997 Oct;85(4):847-53
9322468
Trends Pharmacol Sci. 2001 Mar;22(3):114-20
11239574
AIDS. 1997 Feb;11(2):185-90
9030365
Pain. 1988 Apr;33(1):87-107
2837713
Science. 2001 Aug 31;293(5535):1653-7
11533489
Pharmacol Biochem Behav. 2002 Sep;73(2):429-37
12117598
Anticancer Res. 2005 Jul-Aug;25(4):2681-7
16080512
J Endocrinol Invest. 2004;27(6 Suppl):171-6
15481819
J Neurophysiol. 2007 Jan;97(1):102-9
17050831
Neurosci Lett. 2006 Apr 24;397(3):219-23
16406309
Semin Cell Dev Biol. 2006 Oct;17(5):592-604
17110139
J Pharmacol Exp Ther. 1993 Jul;266(1):329-38
8101218
Nat Neurosci. 2003 Feb;6(2):161-7
12514737
Clin Neurol Neurosurg. 2005 Apr;107(3):181-6
15823672
Neuropharmacology. 2004 Aug;47(2):286-94
15223307
J Peripher Nerv Syst. 1997;2(3):250-2
10975731
J Neurochem. 1981 Apr;36(4):1323-30
6790669
Pain. 2006 Jun;122(3):245-57
16530964
Curr Neuropharmacol. 2006 Jul;4(3):233-7
18615142
AIDS. 2000 Feb 18;14(3):273-8
10716503
IUBMB Life. 2005 Mar;57(3):137-49
16036576
Neuropharmacology. 2005;49 Suppl 1:206-18
15998527